ClinicalTrials.gg
CompletedNCT01410916STEC-HUSUpdated Apr 5, 2013

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

A Phase 2/3 interventional study of Eculizumab (Soliris®) in Shiga-like Toxin-producing Escherichia Coli, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 22 sites in Germany. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2013-04-05.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
2 Months and older
Sex
All
01

Study summary

This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.

02

Conditions studied

  • Shiga-like Toxin-producing Escherichia Coli

Keywords

  • STEC-HUS
  • Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome
  • uncontrolled complement activation
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be willing and able to give written /Assent.
  2. Adults, adolescents, or pediatric (≥2 months and ≥5kg) patients
  3. Patient has been diagnosed with Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

Exclusion criteria

Exclusion Criteria:

  1. Known complement regulatory mutation or family history of complement regulatory mutation
  2. Unresolved systemic meningococcal disease
    1. to eculizumab, to murine proteins or to one of the
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Improvement in Systemic TMA & Vital Organ Involvement at 8 weeks of treatment defined as either complete or partial responder based on hematologic normalization/improvement & clinically important improvement in Vital Organs: Brain, Kidney, and Thrombosis

    Analysis of primary endpoint will occur after all patients have reached 8 weeks of treatment. The response rate will be summarized as patients who are either a complete or partial responder.

    Time frame: 8 weeks

07

Study locations

22 sites
  • Bielefeld, 33615, Germany
  • Bielefeld, 33617, Germany
  • Bonn, 53127, Germany
  • Bremen, 28177, Germany
  • Bremerhaven, 27574, Germany
  • Essen, 45147, Germany
  • Flensburg, 24939, Germany
  • Göttingen, 37075, Germany
  • Hamburg, 20246, Germany
  • Hamburg, 22291, Germany
  • Hamburg, 22359, Germany
  • Hannover, 30625, Germany
  • Karlsruhe, 76133, Germany
  • Köln, 50937, Germany
  • Lubeck, 23538, Germany
  • Magdeburg, 39120, Germany
  • Munchen, 81377, Germany
  • Munich, 80804, Germany
  • Munster, 48149, Germany
  • Oldenburg, 26133, Germany
  • Ulm, 89081, Germany
  • Wildeshausen, 27793, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jan 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2011
First posted
Aug 5, 2011
Start
Jul 2011
Primary completionActual
Jan 2012
CompletionActual
Jun 2012
Last update
Apr 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01410916
Responsible party
Sponsor
First posted
Aug 5, 2011
Start date
Jul 2011
Primary completion
Jan 2012
Completion
Jun 2012
Last update
Apr 5, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion